Effect of Compound Zhebei Granule (复方浙贝颗粒) combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia

Jing Wang; Zong-lang Lai; Xin-yi Chen; Dong-yun Li; Ya-yue Zhang; Wei Ma; Yu-ting Chu; Feng-qin Shi; Lu Yang; Li Hou

doi:10.1007/s11655-015-2117-2

Your Location：

Home >

Browse articles >

Effect of Compound Zhebei Granule (复方浙贝颗粒) combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia

Updated：2021-08-27

- Effect of Compound Zhebei Granule (复方浙贝颗粒) combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia
- Chinese Journal of Integrative Medicine Vol. 22, Issue 6, Pages: 438-444(2016)
- Affiliations：
  
  1. Department of Oncology and Hematology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine,Beijing,China
  2. Department of Oncology, Chongqing Hospital of Traditional Chinese Medicine,Chongqing,China
- Author bio：
- Funds：
  
  Supported by the Specialized Research Fund for the Doctoral Program of Ministry of Education of China (No. 20100013110008)
- DOI：10.1007/s11655-015-2117-2
  CLC：
- Published：2016，
  
  Published Online：14 December 2015，
Scan for full text
Wang, J., Lai, Zl., Chen, Xy. et al. Effect of Compound Zhebei Granule (复方浙贝颗粒) combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia., Chin. J. Integr. Med. 22, 438–444 (2016). https://doi.org/10.1007/s11655-015-2117-2

Jing Wang, Zong-lang Lai, Xin-yi Chen, et al. Effect of Compound Zhebei Granule (复方浙贝颗粒) combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia. [J]. Chinese Journal of Integrative Medicine 22(6):438-444(2016)
Wang, J., Lai, Zl., Chen, Xy. et al. Effect of Compound Zhebei Granule (复方浙贝颗粒) combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia., Chin. J. Integr. Med. 22, 438–444 (2016). https://doi.org/10.1007/s11655-015-2117-2 DOI：

Jing Wang, Zong-lang Lai, Xin-yi Chen, et al. Effect of Compound Zhebei Granule (复方浙贝颗粒) combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia. [J]. Chinese Journal of Integrative Medicine 22(6):438-444(2016) DOI： 10.1007/s11655-015-2117-2.

摘要

To observe the effects of Compound Zhebei Granule (复方浙贝颗粒

CZBG) combined with chemotherapy on surface markers of leukemia stem cell (LSC) in the bone marrow of patients with acute myeloid leukemia (AML). Seventy-eight patients with AML received bone marrow aspiration and the percentages of CD34+ CD123+ and CD33+ CD123+ cells were tested using flow cytometry method. A total of 24 refractory or relapsed AML patients were enrolled and treated with one cycle of standard chemotherapy combined with CZBG. Bone marrow samples were obtained before and after treatment

and the percentages of CD34+ CD123+ and CD33+ CD123+ cells were examined by flflow cytometry. Compared with refractory or relapsed AML patients

patients achieved remission had a significant lower percentage of CD34+ CD123+ cells(P<0.01) and CD33+ CD123+ cells (P<0.01)

indicating that controlling the LSC percentage may be important for patients with AML to achieve sustainable remission. Compared with those before treatment

the expression levels of CD34+ CD123+ were significantly decreased after CZBG combined with chemotherapy treatment (P<0.01). The percentages of CD34+ CD123+ cells and CD33+ CD123+ in patients achieving complete remission after CZBG combined with chemotherapy treatment were both significantly lower than those in patients with nonremission (P<0.01). CZBG combining chemotherapy could reduce the percentages of CD34+ CD123+ and CD33+ CD123+ LSC

which might improve the clinical efficacy of refractory or relapsed AML.

Abstract

To observe the effects of Compound Zhebei Granule (复方浙贝颗粒

and the percentages of CD34+ CD123+ and CD33+ CD123+ cells were examined by flflow cytometry. Compared with refractory or relapsed AML patients

patients achieved remission had a significant lower percentage of CD34+ CD123+ cells(P<0.01) and CD33+ CD123+ cells (P<0.01)

indicating that controlling the LSC percentage may be important for patients with AML to achieve sustainable remission. Compared with those before treatment

which might improve the clinical efficacy of refractory or relapsed AML.

关键词

acute myeloid leukemiaCompound Zhebei GranuleClinical Studyleukemia stem cell

Keywords

acute myeloid leukemiaCompound Zhebei GranuleClinical Studyleukemia stem cell

references

Huang ZH, Chen BA, Ou YJ, Shen ZX, Wang YY, Yu XJ. Epidemiological investigation of leukemia situation and countermeasures in China. J Clin Hematol (Chin) 2009;2:166–167.

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63(1):11–30.

Chang J, Yue GF. Efficacy analysis of refractory acute leukemia. Leukemia 2000;9:44–45.

Lin WY. Current treatment of elderly patients with acute myeloid leukemia. Chin J Gerontol (Chin) 2004;23:284–286.

Mariani SA, Calabretta B. Leukemia stem cells: old concepts and new perspectives. Mol Aspects Med 2014;39:102–109.

Fleischman AG. ALDH marks leukemia stem cell. Blood 2012;119:3376–3377.

Li DY, Tian SD, Ye PZ, Zhang Y, Chen XY. The effects of CZBG adjuvant chemotherapy to improve the clinical efficacy of refractory acute leukemia. J Beijing Tradit Chin Med (Chin) 2007;26:70–72.

Li DY, Zheng Z, Hou L, Chen J, Chen XY. Compound Zhebei Granules drug serum inhibits L1210/CDDP cell proliferation and induced apoptosis. Prog Modern Biomed (Chin) 2009;9:2413–2416.

Zheng Z, Li DY, Chen XY. A drug-combination of Compound Zhebei Granule drug-containing serum affects the accumulation and efflux function and apoptosis of K562/A02 cells. Chin J Integr Chin West Med (Chin) 2010;30:170–173.

Zheng Z, Li DY, Chen J, Liu XY, Chen XY. Effect of Compound Zhebei Granule combined with doxorubicin on inhibition rate of K562/A02 transplanted tumor. Contemporary Med (Chin) 2010;16:5–6.

Zheng Z, Chen J, Li DY, Chen XY. Effect of Compound Zhebei Granule combined with doxorubicin on mdr1 gene expression of K562/A02 transplanted tumor. J Chin Integr Med (Chin) 2009;7:758–762.

Chen XY, Zheng Z, Chen J, Li DY. Effect of Compound Zhe Bei Granule combined with doxorubicin on cell apoptosis and related protein expression of K562/A02 transplanted tumor. J Exp Hematol (Chin) 2009;17:1439–1442.

Zheng Z, Hou L, Xu YM, Li DY, Chen XY. Effect of Compound Zhebei Granule combined with doxorubicin on drug-resistant related enzyme expression of K562/A02 transplanted tumor cells. J Med Res (Chin) 2009;38(12):29–31.

Li DY, Zheng Z, Hou L, Jiang M, Dong Q, Tian SD, et al. Effect of Compound Zhebei Granule combined with doxorubicin on the expression of K562/A02 transplanted tumor cell membrane transporter protein. J Exp Hematol (Chin) 2010;18(1):1–4.

Zhang ZN, Shen T, eds. Diagnosis and standardization of response criteria for blood disease. 2nd ed. Beijing: Science Press; 1998:184.

National refractory acute leukemia seminar. Brief of discussions on diagnostic criteria of refractory acute leukemia. Leukemia • Lymphoma (Chin) 2004;13(2):70.

Zhang ZN, Shen T, eds. Standards of blood disease diagnosis and treatment. 3rd ed. Beijing: Science and Technology Press; 2007:103–116.

Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 1994;367:645–648.

Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730–737.

Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 2011;30:1009–1019.

Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000;14:1777–1784.

Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006;12:1167–1174.

Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009;5:31–42.

Du X, HO M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother 2007;30:607–613.

Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ, et al. Preferential induction of apoptosis for primary human leukemia stem cells. Proc Nad Aead Sci 2009;99:16220–16225.

Guzman ML, Rossi RM, Neelakantan S, Li X, Corbett CA, Hassane DC, et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogebous leukemia stem and progenitor cells. Blood 2007;110:4427–4435.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Integrative oncology meets immunotherapy: New prospects for combination therapy grounded in Eastern medical knowledge

Fuzheng Huayu Capsule (扶正化瘀胶囊) in the treatment of liver fibrosis: Clinical evidence and mechanism of action

Oral herbal medicines for psoriasis: A review of clinical studies

Synergism between carnosic acid and arsenic trioxide on induction of acute myeloid leukemia cell apoptosis is associated with modulation of PTEN/Akt signaling pathway

Alleviation of cancerous pain by external compress with Xiaozheng Zhitong Paste (消癥止痛方)

Related Author

No data

Related Institution

Department of Epidemiology, Mailman School of Public Health, Columbia University

Nuffield Department of Medicine and Department of Primary Health Care, University of Oxford

Global Initiative for Traditional Systems (GIFTS) of Health

Shanghai University of Traditional Chinese Medicine

Guangdong Provincial Academy of Chinese Medical Sciences and Guangdong Provincial Hospital of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰